The following article is a part of conference coverage from the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, being held virtually from February 26 to March 1, 2021. The team at Pulmonology Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the AAAAI 2021 Virtual Annual Meeting.
Patients with mild to moderate atopic dermatitis and comorbid asthma or allergic rhinitis treated with crisaborole had significantly higher treatment success rates compared with vehicle control, according to the results of a post hoc, pooled analysis of 2 phase 3 studies (ClinicalTrials.gov Identifiers: NCT02118766 and NCT02118792) presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting, held February 26 to March 1, 2021.
Investigators compared the Static Global Assessment (ISGA) success rates between groups of patients older than 2 years of age with mild to moderate atopic dermatitis and comorbid asthma or allergic rhinitis treated with either crisaborole or vehicle control Participants were randomly assigned to receive 28 days of treatment with either 2% crisaborole ointment or vehicle control. Success was defined as scoring either a 0 or 1 on the scale with more than 2 unit improvement from baseline.
Of the 641 patients with mild to moderate atopic dermatitis, 399 had comorbid asthma and 242 had comorbid allergic rhinitis. Of the 242 patients with atopic dermatitis and allergic rhinitis, 163 patients received crisaborole and 79 patients received vehicle control. Of the 399 patients with atopic dermatitis and asthma, 258 received crisaborole and 141 received vehicle control. At day 29, ISGA success rates were 36.6% for the treatment group and 18.7% in the vehicle control group among patients with atopic dermatitis and allergic rhinitis (difference, P =.003), and 26.7% for the treatment group and 18.6% in the vehicle control group among patients with atopic dermatitis and asthma (difference, P =.07).
In addition, ISGA score of 0 or 1 occurred in 55.9% of the treatment group vs 29.2% of the control group in patients with comorbid allergic rhinitis and 45.9% of the treatment group vs 31.8% of the control group in patients with comorbid asthma. No new safety concerns were reported.
“Crisaborole demonstrates efficacy and safety in the treatment of mild to moderate [atopic dermatitis] in patients with history of allergic rhinitis or asthma,” the study authors wrote.
Spergel J, Blaiss M, Lio P, et al. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with comorbid allergic rhinitis or asthma. Presented at: the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting; February 26-March 1, 2021. Abstract 89.
Visit Pulmonology Advisor’s conference section for complete coverage of AAAAI 2021 Virtual Annual Meeting.